Medicon Valley and Life science cluster in Denmark
Upcoming SlideShare
Loading in...5
×
 

Medicon Valley and Life science cluster in Denmark

on

  • 2,582 views

 

Statistics

Views

Total Views
2,582
Views on SlideShare
2,582
Embed Views
0

Actions

Likes
0
Downloads
37
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Medicon Valley and Life science cluster in Denmark Medicon Valley and Life science cluster in Denmark Presentation Transcript

    • An Introduction to Danish Life Science - and Medicon Valley Bangalore INDIA BIO 2011
    • AGENDA BIOTECH IN DENMARK MEDICON VALLEY3 August, 2011
    • Denmark & Medicon valley3 August, 2011
    • BIOTECH IN DENMARK The Danish Life Sciences Cluster - facts- 7 science parks - 25 CROs- 8 universities - ≥ 160 core biotech- 75 hospitals (4 major university companies hospitals) - ≥ 180 core medtech- 10,000 life science graduates companies annually - 48,000 employees in the life- 2,000 LS PhDs students science industry graduating annually
    • BIOTECH IN DENMARK DENMARK COMPARES WELL and it is not just something we say...• Denmark is among the five countries in the world (and 2nd in Europe) with the most likely potential for development of biotechnology (Scientific American 2010)• The 3rd best overall biotech sector in the world (fDi Magazine, 2008)• Stable funding situation in the middle of a financial storm (Ernst and Young 2010)• The 3rd largest commercial drug development pipeline in Europe (in actual numbers) (Ernst and Young 2010)
    • BIOTECH IN DENMARK Denmark – European TOP 3 position (pipeline) Preclinical: Phase I: Phase II: Phase III: Research 69 59 58 40(Total commercial drug development pipeline in Denmark Source: Investin Denmark, 2010; Copenhagen Capacity 2010) 6 Source: Ernst & Young, Beyond borders 2010
    • BIOTECH IN DENMARKTHE POOL OF BIOTECH´S KEEPS GROWING New Biotech Start-ups in Denmark 20 18 16 14 Antal start-ups 12 10 8 6 4 2 0 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 1925-1950 1951-1975 1976-1985 1986-1990 1991-1995 until 1925 7 Source: Danish Biotech Ass., December 2009
    • BIOTECH IN DENMARKTOTAL NUMBER OF BIOTECH COMPANIES IN DENMARK 180 160 140 120 Antal virksomheder 100 80 60 40 20 0 Indtil… 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 8 Source: Danish Biotech Ass., December 2009
    • BIOTECH IN DENMARK Denmark is among the largest exporters per capita of pharmaceutical products Development in Danish drug exports 1997-2010: 60 50 40Billion DKK 30 20 10 0 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
    • INVEST IN DENMARK THE DANISH LIFE SCIENCE CLUSTER HOLDS AREAS OF GLOBAL BUSINESS EXCELLENCE & STRONGHOLDS BIOTECH MEDTECH ICT CANCER DIAGNOSTICS ASSITIVE METABOLIC TECHNOLOGY CNS DISPOSABLES INFLAMATORY &INFECTION DISEASES ROBOTICS HEALTHCARE IT
    • BIOTECH IN DENMARK Danish competences – Biotech clusterAreas of Business Excellences Biotech strongholds (Technological platforms)- Cancer/oncology - Biomedical Informatics- CNS/Neuroscience - Clinical Trials - Personalized Medicine- Metabolic diseases - Proteomics- Inflammatory and Infectious diseases - Nanomedicine - Drug Delivery - Vaccines
    • BIOTECH IN DENMARKLife Science centres in Denmark Science Parks Innovation Incubators University Hospitals
    • 7 Science Parks The Science Parks holds:• Incubator solutions• Access to VC’s- from pre-seed to seed• A facilitating and knowledge-sharing environment• Access to state-of-the-art lab facilities• Cost-competitive m2 prices• Usually located close to the universities
    • 6 Innovation IncubatorsThe purpose of the innovation incubator scheme is to create anddevelop more knowledge-intensive start-ups with unique skills Innovation incubators: • seeks out and screen risky commercialization ideas invest in commercialization ideas • ensure access to appropriate facilities for the knowledge-based entrepreneurship • advise entrepreneurs on how to maturation the commercializing idea • help entrepreneurs to build contacts with private investors to attracted capital
    • BIOTECH IN DENMARKCLUSTERS IN DENMARK Northern Jutland/Aalborg • Biomedical technology Central Jutland/Aarhus • Biotech/Biomedical technology/Food innovation Funen/Odense • Biomedical technology Copenhagen area • Medicon Valley
    • MEDICON VALLEYMEDICON VALLEY
    • MEDICON VALLEY MEDICON VALLEY – one of Europe´s strongest life science clusters1997 2011
    • MEDICON VALLEYMEDICON VALLEY – BASIC FACTS & FIGURESPopulation: 3.5 mill. 44.000 life-science7 large R&D based employees in the privatepharma companies with sectorlocal roots 9 science parksApp.150 biotechs with 11 universities (5 supplyown R&D life science educations)App. 200 medtech 155.000 students (appcompanies 1/3 in Life Sciences)More than 50 CROs and More than a dozen VCsCMOs with experienced life33 hospitals (of which 11 science teamsare university hospitals) 18
    • MEDICON VALLEYMEDICON VALLEY STRONGHOLDS• Global leadership in diabetes and obesity• World-class R&D in CNS• Very strong R&D tradition in other important therapeutic areas, e.g. inflammation, infectious diseases, immunology and oncology• Emerging position in the field of personalized medicine
    • MEDICON VALLEYMEDICON VALLEY – where tradition meets the futureTradition: Novo Nordisk, LEOPharma, Lundbeck, Nycomed,Ferring, ALK AlbelloStars of the future: BavarianNordic, Neurosearch, ZealandPharma, Genmab, SantarisPharma, Symphogen, LifecyclePharma, Action Pharma, Exiqon
    • BIOTECH IN DENMARKDanish headline deal makers (selected examples)• Topotarget and Spectrum Pharmaceuticals (2010)• Genmab : GSK (2006) and TenX (2010)• LEO : Buy-back of US psoriasis portfolio from Warner-Chilcott (2009)• LEO : Acquisition of Peplin (AU) for USD 287.5 mill. (2009)• Santaris: Enzon (2006), GSK (2007), Wyeth (2009) and Shire (2009)• Neurosearch: Abbot (1999), GSK (2003) and Eli Lilly (2009), Janssen (2009)• Symphogen: Meiji Seika (2006), Genentech (2008), Origen (2009)• Upfront Chromatography and Cangene (2009)• Egalet and RedHill Biopharma (2009)• Nuevolution: Merck(2008)• Lundbeck: Ovation acquisition (2008)• Zealand: Sanofi-Aventis (2003) and Helsinn (2008)• Zymenex : Divestment of Metazym to Shire (2008)• Exiqon: OncoTech acquisition (2007)• Lifecycle : Mylan (2006), Sandoz (2006) and Sciele (2007)www.mediconvalley.com
    • BIOTECH IN DENMARKBusiness SolutionsChoose DK for your next R&D Center Choose DK for your SalesMarketing office Choose DK for Biopharmaceutical Production Choose DK for your North European HQ The Best Environment for conducting Clinical Trials
    • BIOTECH IN DENMARKDenmark’s best business framework• Flexicurity – easy hire and lay off practices• Best labour relations in the world• Human resources - World’s most motivated and best trained labour force• Flexible and cooperative government – no red tape• 2nd most stable political environment in the world• 25% corporate tax• 3rd best infrastructure in the world• Economic top performer
    • BIOTECH IN DENMARKAssistance from INVEST IN DENMARK• Identification of specific business opportunities Potential partners• Comprehensive fact base and decision-making support Taxation, employment laws, regulatory issues• Local contacts IP consultants, lawyers, authorities & public/private co-operation partners• Tools – unique benchmark, cost/benefit & logistic tools
    • For more information , Pls contact below : PRAMILA DAS , MSc, MBA Investment Manager, LifeSciences INVEST IN DENMARK– INDIA OFFICE M +91 99456 96801 DIR: 91 80 4157 0057 EMAIL PRADAS@UM.DK TRADE COMMISSION OF DENMARK 142, 4th Main Road, Defence Colony Indiranagar, BANGALORE - 560 038 Tel: +91 (80) 4157 0057 WWW.INVESTINDK.COM